[A25-150] Asciminib (CML, first- and second-line treatment) – Benefit assessment according to §35a Social Code Book V
Last updated 21.05.2026
Project no.:
A25-150
Commission:
Commission awarded on 01.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)
- Patients undergoing first-line treatment: hint of a minor added benefit
- Patients who have previously been treated with a tyrosine kinase inhibitor (TKI); second-line treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-150
| Project no. | Title | Status |
|---|---|---|
| A25-70 | Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G22-32 | Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A26-40 | Asciminib (CML, first- and second-line treatment) – Addendum to Project A25-150 | Commission completed |
| G26-09 | Asciminib (CML, first- and second-line treatment) – Second addendum to Project A25-150 | Commission completed |
Federal Joint Committee (G-BA)
21-05-2026 A G-BA decision was published.
G-BA documents on this decision